ADURO BIOTECH, INC. – Trademark Portfolio

Entity Type: 03

ADURO BIOTECH, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include GVAX and ADURO BIOTECH. The owner is based in BERKELEY, CA.

626 BANCROFT WAY; SUITE 3C

BERKELEY, CA 94710

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ADURO BIOTECH, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (5 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does ADURO BIOTECH, INC. have?

ADURO BIOTECH, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned, 4 cancelled.

What trademark classes does ADURO BIOTECH, INC. file in?

ADURO BIOTECH, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ADURO BIOTECH, INC.'s most well-known trademarks?

ADURO BIOTECH, INC.'s registered trademark portfolio includes well-known marks such as GVAX and ADURO BIOTECH. These are among 4 currently registered trademarks in the portfolio.

What is ADURO BIOTECH, INC.'s trademark registration success rate?

ADURO BIOTECH, INC. has a 40% trademark registration rate, with 4 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.